HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (4- isothiocyanatobenzyl)- 1,4,7- triazacyclononane- 1,4,7- triacetic acid

structure given in first source

Also Known As:

2-(4-NCS-Bz)-NOTA

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid: 1
Organic Chemicals: 133
- Isocyanates: 512
  - Isothiocyanates: 501
    - 2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid: 1
- Sulfur Compounds: 278
  - Isothiocyanates: 501
    - 2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid: 1

Experts

1.	Li, Chun: 1 article (04/2020)
2.	Li, Tingting: 1 article (04/2020)
3.	Shi, Sixiang: 1 article (04/2020)
4.	Wang, Yaoqi Alan: 1 article (04/2020)
5.	Wen, Xiaoxia: 1 article (04/2020)
6.	Xiong, Chiyi: 1 article (04/2020)
7.	Zhao, Jun: 1 article (04/2020)

Related Diseases

1.

Neoplasms (Cancer)

04/21/2020 - "We then (1) compared the biodistribution of 64Cu-labeled anti-PD-1 with 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA) and 2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) used as the chelators in the orthotopic model; (2) compared the biodistribution of [64Cu]Cu-NOTA-anti-PD-1 and [64Cu]Cu-NOTA-anti-PD-L1 in the orthotopic model; and (3) imaged subcutaneous and orthotopic KRAS* tumors with [64Cu]Cu-NOTA-anti-PD-L1 with and without co-injection of unlabeled anti-PD-L1 as the blocking agent. "

Related Drugs and Biologics

1.	Chelating Agents
2.	2- (4- isothiocyanatobenzyl)- 1,4,7,10- tetraazacyclododecane tetraacetic acid
3.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
4.	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)